Chapter 10 of 25
| Term or setting | What it means |
|---|---|
| Grade | How the cells look under the microscope. |
| Clinical stage | Extent assessed before definitive treatment, using examination, imaging and biopsy. |
| Pathological stage | Extent established using an operation and microscopic examination. |
| Regional nodes | Nearby lymph-node involvement is not automatically distant metastasis. |
| Distant metastasis | Spread to organs away from the original region. |
T, N and M in plain language
T describes the primary tumour: its size and/or involvement of nearby structures. N describes regional lymph-node involvement. M describes distant metastasis. The exact definitions vary by cancer site, and T is not always determined simply by measuring centimetres. The team combines these categories into a stage group using the correct classification.
Clinical stage is based on examination, imaging and biopsy before definitive treatment. Pathological stage uses information from an operation and microscopic examination. A pathological stage may differ because surgery reveals details that scans could not show. Prefixes such as c, p and yp identify different assessment contexts; yp indicates pathological assessment after preoperative treatment.
Which staging edition does this guide use?
This guide uses the AJCC system applicable to each site in 2026, as identified by the American College of Surgeons current-system table. Oral cavity, HPV-negative oropharynx and hypopharynx, larynx, nasal cavity/paranasal sinuses, and cervical nodes with unknown primary remain under the applicable AJCC 8th Edition chapters. Nasopharynx uses AJCC Version 9, effective in 2025. Salivary glands and HPV-associated oropharynx use AJCC Version 9, effective in 2026.
AJCC updates disease sites separately; “AJCC 9 for all head and neck cancer” is therefore incorrect. UICC TNM is another staging system, with its own edition and local implementation. Do not mix AJCC and UICC categories or editions in one calculation. Ask the treating team to record the system, edition/version, date of staging and exact anatomical site. A historic clinical trial may use an older edition.
Oral cavity: depth and regional nodes
For oral-cavity SCC, depth of invasion contributes to the primary-tumour category. The pathologist measures invasion beneath the normal surface reference level. This explains why two lesions with a similar visible width may have different stages. Involvement of structures such as jaw bone also matters.
Extranodal extension—growth outside a lymph node—can affect nodal classification and treatment decisions in relevant settings. The number, side and size of involved nodes are also important. A node containing cancer remains regional disease when it is within the defined drainage region; it should not automatically be called distant metastasis.
HPV-associated oropharynx and nasopharynx
HPV-associated oropharyngeal cancer has a separate stage classification reflecting its biology and outcomes. A patient can have significant neck-node disease yet a lower stage group than would be assigned to an anatomically similar HPV-negative cancer. This does not mean the node is harmless or that treatment can be reduced without evidence.
Nasopharyngeal carcinoma has its own rules because the relevant nearby structures and nodal patterns differ. Imaging of the skull base, areas behind the throat and neck is important. EBV-related information may aid assessment and monitoring, but a blood marker is not a substitute for the full anatomical stage.
Larynx, hypopharynx and other sites
In laryngeal cancer, the exact subsite—above, at or below the vocal cords—and effects on cord movement and nearby structures influence T classification. A relatively small lesion causing fixation or invading cartilage may be more significant than its diameter suggests. Hypopharyngeal rules also account for location and extension, so they should not be borrowed from oral-tongue staging.
Salivary and sinonasal cancers require correct histology and site assignment. A lip lesion may fall under a cutaneous or oral-mucosal pathway depending on where it starts. This guide’s educational TNM explorer therefore explains concepts without calculating a final stage from a few self-entered details.
Early, locally advanced, unresectable and metastatic
Early-stage disease generally means a limited tumour burden, but the label must be interpreted within its site-specific system. Locally advanced means more extensive disease in the primary region and/or regional nodes; many patients are still treated with curative intent. Unresectable means an operation cannot safely or adequately remove the tumour, not automatically that cure is impossible. Definitive chemoradiotherapy can be curative in suitable settings.
Metastatic disease means spread to distant organs and is usually approached with disease-control and quality-of-life goals. Selected situations need individual discussion. Recurrent disease means cancer has returned after treatment. A local or regional recurrence can sometimes still be treated with curative salvage therapy, so recurrence and incurability are not synonyms.
What to ask about your own stage
Ask for the exact TNM categories, stage group, system/version and whether the stage is clinical or pathological. Then ask what the stage means for the proposed treatment, whether the aim is cure and what additional factors matter. Fitness, swallowing, nutrition, biomarkers and patient priorities can change the plan even when two people share a stage.
Avoid comparing isolated stage numbers with a friend’s cancer or an online survival chart for another site. Stage IV is particularly easy to misinterpret across different head and neck systems. The most useful explanation links your specific findings to the team’s treatment recommendation and the next decision.
References and evidence review
- American College of Surgeons: AJCC Current Staging System (2026)
- American College of Surgeons: AJCC Version 9 protocols
- NCI PDQ: Lip and Oral Cavity Cancer Treatment (2025)
- NCI PDQ: Oropharyngeal Cancer Treatment (2025)
- NCI PDQ: Nasopharyngeal Cancer Treatment (2025)
Evidence/editorial check: 25 October 2026. AI-assisted preparation is distinct from individual physician review. See the linked review policy for source-access limits and review status. Regulatory indications, reimbursement and availability vary by country. Trial results alone do not establish approval everywhere; your treating team should confirm the applicable current guidance.